NADAC acquisition cost data for METAXALONE 800 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00115174801 | $0.5991 | 2022-12-21 | Rx |
| 00185044801 | $0.5991 | 2022-12-21 | Rx |
| 00527143501 | $0.5991 | 2022-12-21 | Rx |
| 00591234101 | $0.5991 | 2022-12-21 | Rx |
| 00904683104 | $0.5991 | 2022-12-21 | Rx |
| 00904683106 | $0.5991 | 2022-12-21 | Rx |
| 50228032301 | $0.5991 | 2022-12-21 | Rx |
| 50228032305 | $0.5991 | 2022-12-21 | Rx |
| 50268053011 | $0.5991 | 2022-12-21 | Rx |
| 50268053015 | $0.5991 | 2022-12-21 | Rx |
Generic: Metaxalone | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $14.1M | 83,373 | 33,164 | $2.24 |
| 2020 | $13.5M | 81,849 | 30,452 | $2.12 |
| 2021 | $13.5M | 84,875 | 32,097 | $2.03 |
| 2022 | $11.5M | 73,194 | 27,507 | $1.99 |
| 2023 | $9.7M | 65,500 | 24,167 | $1.87 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $731.6K | 4,884 | 1,764 |
| Pennsylvania | $631.5K | 4,519 | 1,647 |
| Florida | $614.2K | 3,992 | 1,704 |
| Texas | $598.9K | 4,165 | 1,649 |
| California | $501.0K | 3,111 | 1,031 |
| Michigan | $475.7K | 2,795 | 1,056 |
| North Carolina | $436.4K | 2,825 | 1,040 |
| Ohio | $403.6K | 2,393 | 858 |
| New Jersey | $361.3K | 2,739 | 1,124 |
| Indiana | $324.2K | 2,073 | 683 |
| Maryland | $318.7K | 2,671 | 1,108 |
| Kentucky | $276.8K | 1,904 | 671 |
| Virginia | $264.9K | 1,768 | 675 |
| Georgia | $253.4K | 1,572 | 602 |
| Tennessee | $227.1K | 1,613 | 533 |
| South Carolina | $218.8K | 1,537 | 642 |
| Illinois | $203.4K | 1,405 | 570 |
| Missouri | $184.1K | 1,244 | 431 |
| Alabama | $170.5K | 1,039 | 414 |
| Connecticut | $168.9K | 1,062 | 383 |
| Wisconsin | $167.2K | 1,063 | 348 |
| Oklahoma | $150.3K | 838 | 306 |
| Minnesota | $148.5K | 732 | 195 |
| Massachusetts | $144.5K | 862 | 279 |
| Iowa | $143.3K | 783 | 248 |
| Arizona | $139.6K | 958 | 398 |
| Louisiana | $122.4K | 973 | 344 |
| Puerto Rico | $114.8K | 1,758 | 1,036 |
| Colorado | $102.4K | 717 | 270 |
| Washington | $101.1K | 620 | 192 |
| Oregon | $98.7K | 616 | 203 |
| Kansas | $97.5K | 550 | 185 |
| Delaware | $92.6K | 464 | 179 |
| Nebraska | $80.3K | 444 | 135 |
| Arkansas | $78.9K | 542 | 214 |
| West Virginia | $75.8K | 604 | 215 |
| New Hampshire | $71.6K | 472 | 134 |
| Nevada | $64.6K | 428 | 136 |
| Idaho | $55.4K | 493 | 151 |
| Utah | $53.4K | 501 | 169 |
| Mississippi | $45.2K | 342 | 150 |
| Montana | $37.7K | 237 | 69 |
| New Mexico | $34.1K | 186 | 65 |
| Maine | $33.3K | 125 | 70 |
| Wyoming | $28.8K | 112 | 42 |
| South Dakota | $21.1K | 114 | 40 |
| Rhode Island | $16.3K | 129 | 47 |
| Alaska | $14.4K | 123 | 64 |
| North Dakota | $13.9K | 113 | 39 |
| District of Columbia | $11.0K | 79 | 38 |
| Vermont | $8.5K | 52 | 16 |
| Hawaii | $7.2K | 95 | 42 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.